WAYNE, N.J., Sept. 13, 2011 /PRNewswire/ -- Bayer HealthCare announced today that the company will present data on several of its investigational compounds at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden. These presentations, including the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) data evaluating radium-223 chloride in patients with castration-resistant prostate cancer (CRPC), will highlight the potential of Bayer's growing oncology pipeline.
"We look forward to presenting the complete Phase III data on radium-223 chloride for the first time following the positive results from the ALSYMPCA interim analysis released earlier this year," said Kemal Malik, MD, Head of Global Development and member of the Bayer HealthCare Executive Committee. "These data, along with other presentations from our oncology pipeline, serve to demonstrate Bayer's commitment in cancer."
Studies evaluating Bayer's investigational oncology compounds being presented at ECCO-ESMO include:
A separate 24-month safety analysis from Phase II studies of radium-223 chloride will be presented at the meeting as a poster discussion (Abstract #7008, Poster Discussion Session: Genitourinary Malignancies – Prostate Cancer, Monday, September 26, 2011, 11:00am-12:00pm CEST, Hall A8).
Regorafenib (BAY 73-4506)
About Radium-223 Chloride
Radium-223 chloride is an investigational pharmaceutical containing an alpha-particle emitting nuclide in development for cancer patients with bone metastases. In September 2009, Bayer signed an agreement with Algeta ASA (Oslo, Norway) for the development and commercialization of radium-223 chloride. Under the terms of the agreement, Bayer will develop, apply for global health authority approvals, and commercialize radium-223 chloride globally, while Algeta retains an option for up to 50/50 co-promotion and profit-sharing in the United States.
Radium-223 chloride is an investigational agent and is not approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or other Health Authorities. It was granted fast track designation by the FDA in August 2011.
Regorafenib is an investigational oral multi-kinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases (TK)(i) currently being investigated in clinical trials for its potential to treat patients with various tumor types.
Regorafenib is an investigational agent and is not approved by the FDA, EMA or other Health Authorities.
About Oncology at Bayer
Bayer is committed to advancing the science of cancer, and translating this science into therapies that can help people with cancer live longer. With several compounds in clinical development, Bayer's oncology portfolio demonstrates the Company's commitment to improving the lives of people living with cancer.
About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. As a specialty pharmaceutical company, Bayer HealthCare Pharmaceuticals provides products for Diagnostic Imaging, General Medicine, Hematology, Neurology, Oncology and Women's Healthcare. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.
Heather Levis, Tel. +1 973 305 5313
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
(i) S. Wilhelm, et al. Regorafenib (Bay 73-4506): A New Oral Multikinase Inhibitor Of Angiogenic, Stromal, And Oncogenic Receptor Tyrosine Kinases With Potent Preclinical Antitumor Activity. Online International Journal of Cancer. December 17, 2010.
|SOURCE Bayer HealthCare|
Copyright©2010 PR Newswire.
All rights reserved